CA2065294A1 - Oligonucleotides anti-sens du proto-oncogene c-abl - Google Patents

Oligonucleotides anti-sens du proto-oncogene c-abl

Info

Publication number
CA2065294A1
CA2065294A1 CA002065294A CA2065294A CA2065294A1 CA 2065294 A1 CA2065294 A1 CA 2065294A1 CA 002065294 A CA002065294 A CA 002065294A CA 2065294 A CA2065294 A CA 2065294A CA 2065294 A1 CA2065294 A1 CA 2065294A1
Authority
CA
Canada
Prior art keywords
abl
gca gat
tcc agg
cag gca
gat ctc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002065294A
Other languages
English (en)
Inventor
Bruno Calabretta
Alan M. Gewirtz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education
Publication of CA2065294A1 publication Critical patent/CA2065294A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002065294A 1989-09-01 1990-08-29 Oligonucleotides anti-sens du proto-oncogene c-abl Abandoned CA2065294A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40238389A 1989-09-01 1989-09-01
US402,383 1989-09-01

Publications (1)

Publication Number Publication Date
CA2065294A1 true CA2065294A1 (fr) 1991-03-02

Family

ID=23591651

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002065294A Abandoned CA2065294A1 (fr) 1989-09-01 1990-08-29 Oligonucleotides anti-sens du proto-oncogene c-abl

Country Status (5)

Country Link
EP (1) EP0489846A4 (fr)
JP (1) JPH05500217A (fr)
AU (1) AU646643B2 (fr)
CA (1) CA2065294A1 (fr)
WO (1) WO1991003260A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
WO1993008845A1 (fr) * 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Traitement par application localisee d'oligonucleotides
WO1994010302A1 (fr) * 1992-10-29 1994-05-11 Boehringer Mannheim Gmbh Vecteur amplifiable agissant a l'encontre de la replication du vih
WO1994013793A1 (fr) * 1992-12-04 1994-06-23 Apollon, Inc. Composes et methodes de traitement des leucemies
JPH09503381A (ja) * 1993-07-09 1997-04-08 ジ・インスティテュート・オブ・キャンサー・リサーチ プロテインチロシンキナーゼ及びそのリガンド
WO1997008184A1 (fr) * 1995-08-30 1997-03-06 Arch Development Corporation Procedes et compositions comprenant des agents alterant l'adn et des inhibiteurs ou des activateurs de la tyrosine kinase
JP2003524637A (ja) * 1999-12-23 2003-08-19 エクシコン エ／エス Ｌｎａ修飾オリゴヌクレオチドの治療上の使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
DE3744785A1 (de) * 1987-12-11 1989-08-17 Theurer Karl Eugen Verwendung von ruecklaeufigen spiegelbildlichen anti-sense-nucleinsaeuren gegen krebserkrankungen

Also Published As

Publication number Publication date
WO1991003260A1 (fr) 1991-03-21
AU646643B2 (en) 1994-03-03
EP0489846A1 (fr) 1992-06-17
JPH05500217A (ja) 1993-01-21
EP0489846A4 (en) 1992-06-24
AU6410790A (en) 1991-04-08

Similar Documents

Publication Publication Date Title
US5652222A (en) Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
US5734033A (en) Antisense oligonucleotides inhibiting human bcl-2 gene expression
JP4177455B2 (ja) 逆キメラおよびハイブリッドオリゴヌクレオチド
US5990088A (en) Method for treating kaposi's sarcoma with antisense oligonucleotides
US5744460A (en) Combination for treatment of proliferative diseases
US6277832B1 (en) Growth inhibitor for leukemia cells comprising antisense oligonucleotide derivative to wilms tumor gene (wt1)
AU641636B2 (en) Antisense oligonucleotides to C-MYB proto-oncogene and uses thereof
US6040181A (en) Regulation of bcl-2 gene expression
EP0668782B1 (fr) Combinaison d'un agent anti-neoplasique et d'oligonucleotides antisens dans le traitement du cancer
WO1994023755A1 (fr) Nouveaux procedes et compositions destines au traitement du cancer active par ras au moyen d'oligonucleotides heterotypiques anti-raf et antisens
AU646643B2 (en) Antisense oligonucleotides to C-ABL proto-oncogene
CA2232724A1 (fr) Oligonucleotides modifiees specifiques de la proteine kinase a et leurs modes d'utilisation
WO1997011171A9 (fr) Oligonucleotides modifiees specifiques de la proteine kinase a et leurs modes d'utilisation
JPH09104629A (ja) ウイルムス腫瘍遺伝子（ｗｔ１）に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤
AU3070992A (en) Treatment of melanoma with antisense oligonucleotides to c-myb proto-oncogene
WO1992020348A1 (fr) Traitement de carcinome colo-rectal a l'aide d'oligonucleotides non codants par rapport au proto-oncogene c-myb
US5989849A (en) Antisense of oligonucleotides to c-kit proto-oncogene and in vitro methods
AU2335192A (en) Antisense oligonucleotides to c-kit proto-oncogene and uses thereof
CA1340369C (fr) Oligonucleotides antisens pour le proto-oncogene c-myb et utilisations correspondantes
IL92803A (en) Synthetic antisense oligodeoxynucleotides or phosphorothioate oligodeoxynucleotides as modulators for selective bone marrow cells development and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
FZDE Dead